Pages that link to "Q33897911"

The following pages link to Importance of factor Xa in determining the procoagulant activity of whole-blood clots (Q33897911):

Displaying 45 items.

• Antithrombotic efficacy of a novel factor Xa inhibitor, FXV673, in a canine model of coronary artery thrombolysis (Q28187597) (← links)
• Synthetic and recombinant antithrombin drugs (Q33367033) (← links)
• The role of plaque rupture and thrombosis in coronary artery disease (Q33870602) (← links)
• Activation-dependent exposure of the inter-EGF sequence Leu83-Leu88 in factor Xa mediates ligand binding to effector cell protease receptor-1. (Q34420071) (← links)
• Novel factor Xa inhibitors for prevention and treatment of thromboembolic diseases (Q34549913) (← links)
• The mechanism of action of rivaroxaban – an oral, direct Factor Xa inhibitor – compared with other anticoagulants (Q34624001) (← links)
• Synthetic direct and indirect factor Xa inhibitors (Q34924749) (← links)
• Current anticoagulant therapy--unmet clinical needs (Q35159120) (← links)
• Urinary Prothrombin Fragment 1 2 in relation to Development of Non-Symptomatic and Symptomatic Venous Thromboembolic Events following Total Knee Replacement (Q35367506) (← links)
• Ximelagatran: the first oral direct thrombin inhibitor (Q35753482) (← links)
• New anticoagulants: beyond heparin, low-molecular-weight heparin and warfarin (Q36042279) (← links)
• Rivaroxaban delivery and reversal at a venous flow rate (Q36775716) (← links)
• The coagulation factor Xa/protease activated receptor-2 axis in the progression of liver fibrosis: a multifaceted paradigm (Q37646912) (← links)
• The discovery and development of rivaroxaban, an oral, direct factor Xa inhibitor (Q37821752) (← links)
• The discovery and development of rivaroxaban. (Q37857332) (← links)
• Oral anticoagulants in older adults with atrial fibrillation (Q38076076) (← links)
• Laboratory assessment of rivaroxaban: a review (Q38119016) (← links)
• Pathophysiology of Cardiopulmonary Bypass: Current Strategies for the Prevention and Treatment of Anemia, Coagulopathy, and Organ Dysfunction (Q38215982) (← links)
• Biochemical and pharmacologic rationale for the development of a synthetic heparin pentasaccharide (Q38347007) (← links)
• Novel Antithrombotic Drugs in Development (Q40463597) (← links)
• Evaluation of novel factor Xa inhibitors from Oxya chinensis sinuosa with anti-platelet aggregation activity. (Q41366810) (← links)
• Molecular Basis for the Resistance of Fibrin-Bound Thrombin to Inactivation by Heparin/Serpin Complexes (Q41684212) (← links)
• Prolonged Activation of Prothrombin on the Vascular Wall After Arterial Injury (Q41713905) (← links)
• The use of prothrombin(S525C) labeled with fluorescein to directly study the inhibition of prothrombinase by antithrombin during prothrombin activation (Q43560091) (← links)
• Pharmacological characterization of a novel factor Xa inhibitor, FXV673. (Q43741288) (← links)
• Analysis of the kinetics of prothrombin activation and evidence that two equilibrating forms of prothrombinase are involved in the process (Q44258994) (← links)
• The benefit-to-risk profile of melagatran is superior to that of hirudin in a rabbit arterial thrombosis prevention and bleeding model (Q44518890) (← links)
• Preincubation of Dacron grafts with recombinant tissue factor pathway inhibitor decreases their thrombogenicity in vivo. (Q53772864) (← links)
• Direct thrombin inhibitors (Q56003309) (← links)
• Selective Inhibition of Factor Xa Is More Efficient Than Factor VIIa–Tissue Factor Complex Blockade at Facilitating Coronary Thrombolysis in the Canine Model (Q56945316) (← links)
• Efficacy of local inhibition of procoagulant activity associated with small-diameter prosthetic vascular grafts (Q71765011) (← links)
• Tissue Factor Mediates Prolonged Procoagulant Activity on the Luminal Surface of Balloon-Injured Aortas in Rabbits (Q71807649) (← links)
• Maintenance of Coronary Patency After Fibrinolysis With Tissue Factor Pathway Inhibitor (Q71974509) (← links)
• Role of Thrombin Compared With Factor Xa in the Procoagulant Activity of Whole Blood Clots (Q71974513) (← links)
• In vitro characterization of a novel factor Xa inhibitor, RPR 130737 (Q73023288) (← links)
• Thrombin generation after the abrupt cessation of intravenous unfractionated heparin among patients with acute coronary syndromes: potential mechanisms for heightened prothrombotic potential (Q73081804) (← links)
• Thrombogenicity of small-diameter prosthetic grafts: relative contributions of graft-associated thrombin and factor Xa (Q73293821) (← links)
• Novel Antithrombotic Strategies for the Treatment of Coronary Artery Thrombosis: A Critical Appraisal (Q73295821) (← links)
• [Direct thrombin inhibitors: their role in the treatment of arterial and venous thrombosis] (Q73446080) (← links)
• Inhibition of Tissue Factor–Mediated Coagulation Markedly Attenuates Stenosis After Balloon-Induced Arterial Injury in Minipigs (Q73558502) (← links)
• Molecular basis for the susceptibility of fibrin-bound thrombin to inactivation by heparin cofactor ii in the presence of dermatan sulfate but not heparin (Q73733186) (← links)
• Antithrombotic efficacy of single subcutaneous administration of a recombinant nematode anticoagulant peptide (rNAP5) in a canine model of coronary artery thrombolysis (Q74014924) (← links)
• New antithrombotic agents (Q77397128) (← links)
• Biochemical and pharmacological profile of darexaban, an oral direct factor Xa inhibitor (Q82275205) (← links)
• Venous and arterial thrombosis – pathogenesis and the rationale for anticoagulation (Q83172029) (← links)